XNAS · Healthcare · Biotechnology
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2025-08-07 | Q2 2025 | -0.49 | -0.71 | -44.90% | $0 | ❌ Miss | +0.00% | +0.89% | -1.66% |
| 2025-02-27 | Q4 2024 | -0.73 | -1.02 | -39.73% | $0 | ❌ Miss | -0.97% | -10.84% | -22.00% |
| 2024-11-07 |
| Q3 2024 |
| -0.64 |
| -1.39 |
| -117.19% |
| $0 |
| ❌ Miss |
| +4.92% |
| -12.15% |
| -19.38% |
| 2024-02-29 | Q4 2023 | -0.49 | -0.50 | -2.04% | $0 | ❌ Miss | — | — | — |
| 2023-11-08 | Q3 2023 | -0.53 | -0.45 | +15.09% | $0 | ✅ Beat | -4.86% | -5.23% | +22.79% |
| 2023-03-10 | Q4 2022 | -0.69 | -0.48 | +30.43% | $0 | ✅ Beat | +5.17% | +3.67% | +20.08% |
Showing last 6 quarters.